Catheter Encrustation: What Causes It, and What an In-Vitro Model Can Show

1. What actually causes catheter encrustation?

Catheter encrustation is not a slow chemical deposit from ordinary urine. It is driven by bacteria, and the mechanism is specific enough to design a test around. A urease-producing organism colonises the device, most often Proteus mirabilis. Urease hydrolyses the urea that urine already carries, ammonia is released, and the pH climbs. Above a threshold the urine can no longer hold its calcium, magnesium and phosphate in solution, and crystals come out onto the device: struvite, magnesium ammonium phosphate, and a calcium phosphate phase.

Two things follow from that chain, and both are routinely missed when a study is planned. The pH rise is the driver, not the baseline chemistry, so a fluid that carries the right ions but never rises in pH will not encrust in any useful timeframe. And the process has a threshold rather than a rate: below the pH at which the salts stop being soluble, essentially nothing happens; above it, deposition is rapid. That is why time-to-blockage is the endpoint people measure, and why small differences in the starting chemistry move that time so much.

2. Why is encrustation so hard to prevent, and what is actually tested?

Because the cause is colonisation and the effect is chemical, the strategies that get tested fall into a small number of families, and each one is evaluated on the same endpoint. Surface approaches try to stop the organism attaching in the first place: coatings, low-adhesion polymers, silver and other antimicrobial surfaces. Chemical approaches attack the pH rise itself, with urease inhibitors or with acidic irrigation. Management approaches simply change the device before the threshold is reached, which is why a reliable time-to-blockage figure has clinical value even when nothing about the device changes.

None of these is settled, which is exactly why the in-vitro model matters. A bladder model that reproduces the pH trajectory lets you compare two catheters on the variable you care about, in weeks rather than in a clinical study. What it does not do is predict a patient outcome, and a report that treats a bench time-to-blockage as a clinical claim will be read as overreach.

3. What must an encrustation test fluid contain?

This is where the wrong fluid is most often ordered. An absorbency fluid such as the ISO 11948-1 synthetic urine deliberately carries little calcium, magnesium phosphate or citrate, because those species would encourage crystal formation that an absorbency test has no interest in. Put a catheter in it and nothing encrusts, because the chemistry it needs was deliberately left out.

An encrustation fluid is built the other way round. Formulations of the Griffith and Stickler type carry urea as the urease substrate, together with the calcium, magnesium and phosphate that precipitate once the pH climbs, and usually creatinine, uric acid, citrate and oxalate alongside them. Most protocols then inoculate with the organism so that the pH rises over the incubation the way it does in a colonised bladder. For long flow-rig runs a sterile starting fluid matters, because unintended contamination changes the pH trajectory and therefore the result.

4. Which standard should an encrustation study cite?

There is no horizontal ISO or EN standard that governs an encrustation test the way EN 1811 governs nickel release. The bladder-model work sits in the research literature, and protocols vary between laboratories in flow rate, in inoculum and in how blockage is declared. Say so in the report rather than implying a standard exists.

Separately, if your technical file still cites EN 1616 for the catheter itself, check it before your next audit. EN 1616:1997 was withdrawn: urethral catheters are covered by EN ISO 20696:2018 and drainage catheters by ISO 20697:2018. Those standards address the mechanical requirements on the device, not the encrustation study, and the two are often confused on the same purchase order.